TOL101

Abstract: For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation-dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.

Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided

Abstract: Despite significant advances in the field of kidney transplantation resulting in decreased rates of acute rejection, there remain several areas in which the development of new drugs and therapies could potentially change the landscape and have a major impact on long-term graft survival. These include the optimization of organ quality prior to and at the time of transplantation, the control of inflammation in the allograft, and the avoidance or minimization of adverse effects associated with conventional immunosuppression. This chapter focuses on emerging strategies for the prevention and treatment of delayed graft function, new agents that carry the promise of safer and more effective costimulation blockade, and finally, innovative therapies to control the humoral arm of the immune system. The current status of development of these drugs and the challenges facing their utilization are discussed.

Abstract: The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided